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Abstract Cranial neuralgias are paroxysmal painful dis-
orders of the head characterised by some shared features
such as unilaterality of symptoms, transience and recur-
rence of attacks, superficial and “shock-like” quality of
pain and the presence of triggering factors. Although rare,
these disorders must be promptly recognised as they har-
bour a relatively high risk for underlying compressive or
inflammatory disease. Nevertheless, misdiagnosis is fre-
quent. Trigeminal and glossopharyngeal neuralgias are
sustained in most cases by a neurovascular conflict in the
posterior fossa resulting in a hyperexcitability state of the
trigeminal circuitry. If the aetiology of trigeminal neural-
gia (TN) and other typical neuralgias must be brought
back to the peripheral injury, their pathogenesis could
involve central allodynic mechanisms, which, in patients
with inter-critical pain, also engage the nociceptive neu-
rons at the thalamic-cortical level. Currently available
medical treatments for TN and other cranial neuralgias
are reviewed.
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Introduction
Cranial neuralgias are paroxysmal painful disorders of
the head, rarely seen in clinical practice. They are charac-
terised by some shared features, such as unilaterality of
symptoms, transience and recurrence of attacks, superfi-
cial and “shock-like” quality of pain, and the presence of
triggering factors. Although trigeminal neuralgia (TN)
and glossopharyngeal neuralgia are sustained in most
cases by a neuro-vascular conflict in the posterior fossa,
cranial neuralgias share a relatively high risk for a com-
pressive underlying cause different from the neurovascu-
lar conflict.
Classification, epidemiology and clinical aspects
The second edition of the International Classification of
Headache Disorders (ICHD-II) [1] codes the cranial neu-
ralgias in Chapter 13 and provides the diagnostic criteria
for 18 different subtypes (Table 1) including a number of
heterogeneous central causes of facial pain, which will
not be discussed here. 
Trigeminal neuralgia
Classification and epidemiology
According to the ICHD-II the diagnosis of Classical
Trigeminal Neuralgia has to fulfil the criteria listed in
Table 2. These criteria must be also present in
Symptomatic Trigeminal Neuralgia but in the latter form
additional signs and symptoms such as a mild ache
between attacks and the presence of sensorial defect in
the affected territory are admitted. The boundary between
classical and symptomatic forms of TN is therefore rather
Neurol Sci (2008) 29:S69–S78
DOI 10.1007/s10072-008-0892-7
C R A N I A L  N E U R A L G I A S
Cranial neuralgias: from physiopathology to pharmacological
treatment
Roberto De Simone • Angelo Ranieri • Leonilda Bilo •
Chiara Fiorillo • Vincenzo Bonavita
© Springer-Verlag 2008
R. De Simone () · A. Ranieri · C. Fiorillo
Department of Neurological Sciences
University “Federico II” of Naples
Via Pansini 5, 80131 Naples, Italy
e-mail: rodesimo@unina.it
L. Bilo · V. Bonavita
Istituto di Diagnosi e Cura Hermitage Capodimonte
Naples, Italy
S70 Neurol Sci (2008) 29:S69–S78
frail and neuroimaging investigations are highly recom-
mended, especially in the cases of recent onset.
Although TN is the most common among the cranial
neuralgias, with an incidence of 3–5 new cases for 100,000
subjects per year [2] and a prevalence of 15.5 cases per
100,000 [3], it is still to be considered a rare disease. TN
can appear at any age, but the onset is after age 40 in 90%
of the cases; women are more likely to be affected than
men, with a gender ratio of 2:1. About 2% of the patients
with multiple sclerosis (MS) can experience a pain disorder
nearly identical to TN [4]; despite the evidence of a sub-
stantial clinical overlap [5], neuralgias related to MS are
not classified among symptomatic forms, but in a specific
subgroup of the same ICHD-II chapter (13.18.3. Facial
Pain Attributed Multiple to Sclerosis).
Clinical aspects
The pain in TN usually occurs in brief paroxysmal
attacks either isolated or in short clusters. Typically, it is
felt superficially and is described as extremely severe
and of burning or “shock-like” quality. Attacks tend to
be stereotyped and are strictly confined to the territory of
distribution of one or more branches of the trigeminal
nerve of a single side. The maxillary and mandibular
nerves, in combination or alone, are more often affected
than the ophthalmic nerve, which is involved alone in
less than 5% of cases [6]. The single attack lasts charac-
teristically from less than a second to a few seconds, but
it can be present in clusters up to 2 min in length; in
many cases it is followed by a brief refractory period
during which a new stimulation is not able to evoke the
Table 1 ICHD-II classification of cranial neuralgias
13. Cranial neuralgias and central causes of facial pain
13.1 Trigeminal neuralgia
13.1.1 Classical trigeminal neuralgia
13.1.2 Symptomatic trigeminal neuralgia
13.2  Glossopharyngeal neuralgia
13.2.1 Classical glossopharyngeal neuralgia
13.2.2 Symptomatic glossopharyngeal neuralgia
13.3  Nervus intermedius neuralgia
13.4  Superior laryngeal neuralgia
13.5  Nasociliary neuralgia
13.6  Supraorbital neuralgia
13.7  Other terminal branch neuralgias
13.8  Occipital neuralgia
13.9  Neck-tongue syndrome
13.10 External compression headache
13.11 Cold-stimulus headache
13.11.1 Headache attributed to external application of a cold stimulus
13.11.2 Headache attributed to ingestion or inhalation of a cold stimulus
13.12 Constant pain caused by compression, irritation or distortion of cranial nerves or upper cervical roots by structural lesions
13.13 Optic neuritis
13.14 Ocular diabetic neuropathy
13.15 Head or facial pain attributed to herpes zoster
13.15.1 Head or facial pain attributed to acute herpes zoster
13.15.2 Post-herpetic neuralgia
13.16 Tolosa-Hunt syndrome
13.17 Ophthalmoplegic ‘migraine’
13.18 Central causes of facial pain
13.18.1 Anaesthesia dolorosa
13.18.2 Central post-stroke pain
13.18.3 Facial pain attributed to multiple sclerosis
13.18.4 Persistent idiopathic facial pain
13.18.5 Burning mouth syndrome
13.19 Other cranial neuralgia or other centrally mediated facial pain
Table 2 ICHD-II criteria for 13.1.1 Classic trigeminal neuralgia
13.1.1 Classic trigeminal neuralgia
A. Paroxysmal attacks of pain lasting from a fraction of a second to 2 minutes, affecting one or more divisions of the trigeminal nerve
B. Pain has at least one of the following characteristics:
1.   Intense, sharp, superficial or stabbing
2.   Precipitated from trigger areas or by trigger factors
C. Attacks are stereotyped in the individual patient
D. There is no clinically evident neurological deficit
E. Not attributed to another disorder
pain. The location of the pain is typically unilateral, but
it can be bilateral in patients with MS, although asyn-
chronously. Interestingly, the right side is more often
involved than the left. The disorders seldom affect more
members of the same family [7, 8]. The attacks can occur
spontaneously or they can be provoked by stimulation of
specific trigger areas. These are often localised in the
skin around the mouth and at the sides of the nose, due
to its higher sensorial innervation, and can also involve
the gums. In rare cases the attacks are evoked by extra-
trigeminal triggers, such as olfactory or gustatory stimuli
[9]. Characteristically, tactile stimuli can trigger an
attack while painful stimuli usually do not. Furthermore,
the provoking stimuli fall within a physiological range of
intensity like those arising from normal daily activities:
brushing teeth, shaving, chewing, yawning or swallow-
ing. Quite often patients can experience a muscle spasm
involving the mimic muscles occasionally associated
with other involuntary movements. The presence of
unintentional movements have led to the term “tic
douloureux”, often used to indicate this condition.
Involvement of the autonomic nervous system is not usu-
ally present, but when the ophthalmic nerve is affected it
is possible to observe a modest tearing discharge without
conjunctival injection or any other autonomic sign.
These cases create problems of differential diagnosis
with the rare primary headache coded in the ICHD-II as
sudden onset unilateral neuralgiform headache attacks
with conjunctival injection and tearing (SUNCT).
Differential diagnosis between TN and SUNCT depends
on the different intensity and variety of autonomic symp-
toms involved [10].
Clinical course
The onset of a typical TN is quite often preceded by a
painful condition affecting mandibular or maxillary
areas. The pain can be variable but it usually resembles
the pain of a sinus infection or toothache. This condition
is named pretrigeminal neuralgia [11]. It can precede the
onset of typical neuralgic symptoms by years and can
present with episodes of long-lasting facial pain some-
times triggered by chewing or drinking warm or cold
foods. Pretrigeminal neuralgia is responsive to the spe-
cific drug treatments for TN and represents a common
cause of misdiagnosis in the early phases of disease. The
clinical course of the definite disease is very often inter-
mittent; spontaneous remissions of at least 6 months are
described in 50% of cases and remissions of at least one
year in about 25% of patients [12]. Nevertheless, the
usual pattern is for a progressive worsening with
increased severity and frequency of pain, prolonged
duration of the active phases, lower response to drugs,
possible development of constant soreness between
attacks (inter-critical pain) and clinically evident defects
of trigeminal sensory function. 
Diagnosis
A clinical presentation with brief attacks of strict unilat-
eral shock-like pain within trigeminal areas and the pres-
ence of typical trigger areas makes this condition easy to
recognise. Nevertheless TN is often misdiagnosed in
patients affected by cluster headache or sometimes by a
side-locked migraine; conversely the correct diagnosis
can be delayed until the failure of inappropriate odon-
tostomatological treatments [11].
Like most typical neuralgias, TN is symptomatic in
5%–10% of symptomaticity cases [13]. The recent
ICHD-II revision of the International Headache Society
(IHS) classification considers the presence of inter-criti-
cal pain and sensory deficits as possible predictors of a
structural cause; however inter-critical pain and sensory
deficits have low specificity [14] and must be cautiously
taken into account, especially in cases with a long dura-
tion of illness [15]. A possible structural cause must be
considered in case of onset before 40 years, bilaterality of
the symptoms, presence of neurological signs or atypical
pain in terms of quality, affected area, intensity or dura-
tion. In these conditions extensive neuroimaging studies
are highly recommended. Arterial hypertension is consid-
ered a possible risk factor [16]. Included among the pos-
sible causes of secondary TN are: MS; Charcot-Marie-
Tooth disease [17], meningiomas, neurinomas and other
slow-growing tumours of posterior cranial fossa;
syringobulbia; arachnoiditis; basilar artery and internal
carotids aneurysms; fractures of the cranial base; and her-
pes zoster.
Recent evidence [18] suggests that trigeminal reflex-
es studies by blink reflex and laser evoked potentials
(LEPs) can differentiate symptomatic TN from classic
TN more reliably than any other clinical data, including
age of onset. Therefore such techniques could be per-
formed to select those patients who need to be further
investigated with neuroimaging.
Glossopharyngeal neuralgia
Neuralgia of glossopharyngeal nerve (GFN) is a rare
entity with an estimated incidence of 0.8 cases per 
100,000 [2]. As a matter of fact, authors from the Mayo
Clinic have reported only 217 cases in 55 years [19]. The
prevalence, compared to NT, is of about 1 case of GFN
for every 75 of TN [18]. As for other neuralgias, this
form is separated into Classical and Symptomatic, which
differ mostly by the presence of inter-critical pain and
sensory deficit in the territories of distribution of the
nerve. The ICHD-II diagnostic criteria for the Classic
form of GFN are shown in Table 3. The term Classical,
which is also used for TN, has been introduced to make
the diagnosis compatible with the presence of neurovas-
cular conflict in posterior fossa. Males and females are
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equally affected. Interestingly, the left nerve is more
often involved than the right one [20]. 
From a clinical point of view GFN shares the same
basic features of TN with a typical neuralgic pain occur-
ring in a paroxysmal way. Pain is habitually located in
the tonsillar region and in the back of the pharynx, with
possible transmission to the lower portion of the jaw and
to the ear. The painful attacks can be triggered by ordi-
nary activity such as swallowing, chewing, speaking,
coughing, sneezing, throat-clearing or by head rotation.
The association with NT is not rare, accounting for about
10% of cases [6]. The clinical course is usually episodic,
with active phases lasting weeks or months and off-pain
periods of different length. Pain attacks are described to
worsen in frequency or severity over time, whereas the
remission phases tend to shorten. 
The pain episodes usually last from less than a second
up to 2 min but sometimes they can occur in rapid and con-
tinuous sequence (status neuralgicus). When the pain is
triggered by swallowing, feeding can be impaired for long
periods and it is not rare for these patients to undergo a
striking weight loss. Unilaterality is a key sign and when
the pain is bilateral a possible association with MS must be
suspected. In about 2% of cases, patients can experience
severe bradycardia with subsequent lost of consciousness
[6]. Similarly to TN, the risk of an underlying cause is rel-
atively high and it is always advisable to perform a wide
diagnostic work-up in these patients.
Causes of symptomatic GFN are: tumours of the cere-
bellumpontine angle, nasopharyngeal carcinomas,
aneurysms of the carotid, abscesses of tonsils, rare neurino-
mas of the IX nerve and MS. Worth noting is the syndrome
of the stylohyoid apophysis (Eagle’s syndrome) [21], in
which the neuralgic symptoms are due to irritation of the
glossopharyngeal nerve in its esocranial path when stylo-
hyoid process is longer than normal (over 4.5 cm instead of
2.5 cm). Local anaesthesia (lidocaine 10%) of pharyngeal
and tonsillar triggers areas has diagnostic value. 
Nervus intermedius neuralgia
Also known as geniculate or Hunt’s neuralgia, this form
is among the less frequent of the series. Typical clinical
features are [22]: paroxysmal unilateral pain lasting
from seconds to a few minutes localised deeply in the
ear; radiation of pain to the external auditory meatus;
occurrence of vegetative symptoms such as abnormal
tearing and salivation, taste problems; relapsing course
with active phases of disease and symptom-free periods;
and higher prevalence in females. Geniculate neuralgia
is often correlated with shingles of the external auditory
duct.
Occipital neuralgia
Occipital neuralgia is classically characterised by unilater-
al paroxysmal pain in the areas corresponding to location
of lesser and greater occipital nerves. The pain can be asso-
ciated to inter-critical pain and dysaesthesia [23]. The dis-
ease can occur after traumas of the occipital area, even if
they are irrelevant, whereas it can be also sustained by
numerous medical conditions such as Arnold-Chiari mal-
formation, bone and joint diseases, herpetic neuropathies
and masses that can compress the nerve along its path [24].
The pure form (Arnold neuralgia) is very rare com-
pared to the countless syndromes affecting cervical
spine, with which it shares some overlapping features. A
selective tenderness after pressure on trigger points is
also reported.
Superior laryngeal nerve neuralgia
This is an extremely rare form. It is characterised by
paroxysmal pain of the lateral part of throat, of the sub-
mandibular region, around the ear and along the neck; the
paroxysms can be triggered by chewing, and head exten-
sion or rotation [25]. The superior laryngeal nerve is a
branch of the vagus nerve and it is involved in the senso-
rial-motor innervation of the larynx and in the glottic
reflex. It enters the larynx crossing the lateral aspect of
the hyoid membrane. The pain, habitually unilateral,
occurs in attacks of a few minutes that re-occur up to
10–30 times in 24 h with clustering of different length
and tendency to the remission. The attacks can be associ-
ated to an uncontrollable cough and can be triggered by
compression of the point of entry through the hyoid
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Table 3 ICHD-II criteria for 13.2.1 Classical glossopharyngeal neuralgia
13.2.1 Classical glossopharyngeal neuralgia
A. Paroxysmal attacks of facial pain lasting from a fraction of a second to 2 minutes and fulfilling criteria B and C
B. Pain has all of the following characteristics:
1. Unilateral location
2. Distribution within the posterior part of the tongue, tonsillar fossa, pharynx or beneath the angle of the lower jaw and/or in the ear
3. Sharp, stabbing and severe
4. Precipitated by swallowing, chewing, talking, coughing and/or yawning
C. Attacks are stereotyped in the individual patient
D. There is no clinically evident neurological deficit
E. Not attributed to another disorder 
membrane, sideways and immediately above the larynx.
Benefits emerging from anaesthesia of these regions are
of diagnostic value. 
Pathophysiology of the cranial neuralgias
Over the last decades cranial neuralgia pathophysiology
has been partly clarified by important research contribu-
tions supporting the causative role of a chronic irritation
of the affected nerve due to compressive or inflammato-
ry causes. Nevertheless, evidence suggests that central
factors can contribute to the development of these forms.
The following considerations refer to TN, however it is
supposed that also other typical painful diseases of the
face, such as glossopharyngeal neuralgia, share similar
mechanisms [6]. 
In 1976 Jannetta  [26] published the first extensive
case study of subjects with TN in all of which, after
investigations of posterior cranial fossa, a causative fac-
tor was documented. Besides slow-growing tumours of
the cerebellumpontine angle accounting for 6% of the
patients, and MS found in another 6% of the cases, in
88% of the subjects a compression of the proximal tract
of the root of the V nerve by one or more tortuous or
ectasic blood vessels was recognised (Fig. 1). In the site
of the neurovascular conflict a demyelination was con-
stantly present. As placing a teflon pad between the two
structures – so-called microvascular decompression
(MVD) – immediately stopped the attacks, the focal
demyelination of the nerve was proposed as the main
causative factor. The observations of these Authors have
inspired a great deal of research paving the way to impor-
tant progress on TN mechanisms which led to including
this condition, notwithstanding relevant dissimilarities,
in the broader chapter of neuropathic pain.
Much evidence sustains the causative role of a proxi-
mal compression of the trigeminal nerve root including:
high frequency of neuroimaging positive report docu-
menting a neurovascular conflict [27]; the prompt resolu-
tion of symptoms and nerve conduction defects after
MVD [28, 29]; and ultimately the gradual remission of
sensory defects of clinical relevance after surgery [30].
Mechanisms of the pain
It is noticeable that the conflict always involves the prox-
imal portion of the trigeminal root, the so-called root
entry zones (REZ). Myelin at this level is still of central
type and this could impact the resistance of the nerve to
mechanical stimuli [31]. The compression probably caus-
es a mechanical twist of the fibres and their secondary
demyelination, probably mediated by microvascular
ischaemic damages [32]. These changes can significantly
lower the excitability threshold and promote an inappro-
priate ephaptic propagation towards adjacent fibres [33].
Because of the cross-talk, the tactile signals coming from
the fast myelinic fibres (A-beta) can directly activate the
slow nociceptive fibres (A-delta) and produce repetitive
high-frequency discharges responsible for the typical
“lightening” pain triggered by tactile stimuli. After a few
seconds or minutes the repetitive discharges spontaneous-
ly run out and are followed by a brief period of inactivity
that explains the “refractory period” clinically evident in
many cases [34]. The aetiological role of the focal
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Fig. 1 A triple neurovascular conflict (Courtesy
of Prof. P. Cappabianca – Neurosurgery,
University of Naples “Federico II”, Naples, Italy)
demyelination of the REZ also explains the increased
prevalence of NT in subjects with MS, in which demyeli-
nated foci in the mid-pons and the REZ are usually
demonstrated [35, 36]. Demyelination and remyelination
processes observed in electronic microscopy studies [37]
could also explain the typical periodicity of the syndrome. 
Although these observations seem to point out that a
demyelination of the REZ secondary to tumours, neu-
rovascular conflict or MS is the causal element in all the
cases of NT, different observations suggest that the hyper-
excitability of the compressed nerve could represent a nec-
essary condition, still not sufficient to cause the disease.
Several autoptic case studies document a high prevalence
of neurovascular conflicts at the proximal level in asymp-
tomatic individuals [38–40]; a compression of REZ is not
demonstrated in all the patients [41]; at least initially the
pain is effectively treated by drugs such as baclofen, which
is considered non-active on the peripheral fibres; familiar
cases in which a neurovascular conflict is not detectable
have been reported [8]. All these observations suggest a
possible involvement of relevant central factors. 
It has been suggested that a hypersensitivity of the tac-
tile A-beta nerve fibres, initiated by the same nerve injury,
leads to a sensitisation of the wide dynamic range neurons
(WDRn) [42]. These peculiar nociceptive neurons are
placed both in the V lamina of the dorsal horns and in the
trigeminal nerve nuclei and are characterised by a progres-
sive facilitation of excitability following repeated stimula-
tion. Since these peculiar nociceptive II order neurons
receive convergent information from both tactile A-beta
and nociceptive A-delta and C fibres, their sensitisation
can ultimately facilitate nociceptive input at the central
level while promoting the perception of pain in response to
tactile stimuli, a phenomenon called allodynia. The high
prevalence of neurovascular conflicts in autoptic studies of
asymptomatic subjects suggests that an individual predis-
position to allodynic pain could be of great relevance in
TN mechanisms. Noteworthy, allodynic sensitisation of
thalamic nociceptive neurons has been recently document-
ed in NT patients presenting with a continuous pain
between attacks [14], a condition associated with a poor
medical and surgical outcome [43]; interestingly, in this
study the illness duration was not related to the presence of
inter-critical pain, confirming its low specificity as a mark-
er of symptomatic form or of protracted diseases. 
Findings from recent studies on animal models point to
dorsal root ganglia as a new site possibly involved in neu-
ropathic pain and TN mechanisms [44]. At this level, a
chemically mediated cross-talk between somata of both
tactile A-type and nociceptive C-type sensory neurons has
been recorded in physiologic conditions [45]. The mecha-
nism results in a reciprocal excitability threshold modula-
tion probably aimed to balance pain and tactile excitabili-
ty in different physiologic conditions. In the presence of an
injury-driven nerve sensitisation, the threshold for a cross-
excitation between sensitised A and C fibres can be
reached at the dorsal root ganglia level [46] and this may
lead to pain generation in response to tactile stimuli. A
possible involvement of Gasser ganglion in TN pathogen-
esis is supported by the finding of histological changes at
this level both in Classic TN patients [47] and in subjects
with TN associated to MS [48]. 
These observations link the pathophysiology of TN to
a hyperexcitability of the trigeminal circuitry sustained
by peripheral and central mechanisms. If the aetiology of
TN and other typical neuralgias must be brought back to
the peripheral injury, their pathogenesis could involve
central allodynic mechanisms, which, in patients with
inter-critical pain, also engage the nociceptive neurons at
the thalamic-cortical level. 
Treatment
TN can be treated with drugs or surgical procedures;
many patients end up with both treatments, although at
different times. As a matter of fact, medical therapy
works very well at the beginning and reaches almost
complete control of symptoms in more than 80% of
patients. As time passes, drugs progressively lose effica-
cy even if they are in multiple therapy. In these cases pos-
sible surgical options must be taken into account.
Interestingly most of the drugs that are effective in TN
have anti-epileptic activity or, in the case of baclofen,
have effect on the central transmission of pain. This fact
supports the hypothesis of the hypersensitivity of trigem-
inal circuitry following a nerve injury in the pathogene-
sis of TN. Historically phenytoin, used for the first time
in 1942 by Berguignon, was the first drug to be reported
to be effective in the treatment of TN. Only in 1962 with
the introduction of carbamazepine did patients with TN
begin to benefit from a truly effective treatment with a
satisfying tolerability [6].
Despite the lack of randomised and controlled studies
of large samples, due to the rarity of the disease and eth-
ical difficulties in using placebo in such a devastating
condition, the spectrum of available drugs has grown in
time, adding several other anti-epileptic drugs (AED).
Recently, medications that inhibit the transmission of the
pain to the central II order neurons such as subcutaneous
sumatriptan [49], or treatments with possible action
against allodynia like the botulinum toxin [50, 51] have
been found effective in pain control. Following is a list of
the evidence on the efficacy of the main drugs used in
clinical practice for the treatment of these forms.
Anti-epileptic drugs
Carbamazepine (CBZ)
Carbamazepine is considered the mainstay for treating
these disorders. It is also the only molecule for which
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there is a great deal of evidence (1 systematic review and
4 RCT studies) [52]. Carbamazepine reduces sodium-
channel conductivity, stabilising the membrane of pre-
and post-synaptic neurons and making trigeminal
mechanoceptors less prone to respond to peripheral
input. About 80% of patients benefit from this treatment
and in 94% of patients there is relief from symptoms in
the first 48 h of treatment [53, 54]. As time passes how-
ever, the efficacy tends to be lower [55]. The recom-
mended starting dose is 100 mg twice a day; this can be
increased by 50–100 mg every 3–4 days up to a final dose
of 400–1000 mg to continue until symptoms persist. The
most common side effect is drowsiness, however this
tends to decrease after a few days of treatment. 
Other side effects are cerebellar symptoms, double
vision, haematological changes, liver disease, skin rash,
nausea and vomiting [56]. Intolerance is seen in 5%–19%
of patients. 
Oxcarbazepine
Oxcarbazepine is structurally a derivative of carbazepine,
therefore it shares carbamazepine’s mechanism of action.
It can be used if intolerance to carbamazepine is present,
or alternatively as the drug of choice [57]. Clinical trials
on small groups of patients report that the drug is effec-
tive in 24 h and some report a greater efficacy and toler-
ability compared to carbamazepine [58]. The initial dose
is 150 mg, which can be increased every 3 days of by
150–300 mg up to a therapeutic dose of 1200 mg three
times a day. 
Phenytoin
This is a drug of second or third choice and can added in
case of intolerance or low efficacy to carbamazepine. The
suggested mechanism of action is stabilisation of the
CNS neuron’ membrane, modulating sodium channels.
Initially the drug is reported to be effective in 60% of
patients, but after two years of treatment the efficacy is
reduced to about 30%. The recommended starting dose is
200 mg, to be increased to a therapeutic dose of 300–500
mg twice a day. Injectable formulation, with a dose of
250 mg can be used for acute treatment of pain attacks
and reaches a pain-free period of 4–72 h [59]. Side
effects include double vision, ataxia, liver disease, gum
hyperplasia, haematologic disturbance, hirsutism and
memory defects. 
Gabapentin
Gabapentin is widely used in the treatment of TN
although its efficacy has been reported in few non-con-
trolled studies. It has been empirically used because of its
proven efficacy in pain control in post-herpetic and dia-
betic neuropathies [60]. It has been suggested that
gabapentin acts by increasing GABA availability in the
CNS and modulates the voltage-gated sodium channel,
resulting in a reduced discharge of excitatory neurotrans-
mitters. About 50% of patients respond to therapy after
3–4 days of treatment. A full remission from symptoms
is achieved after about 2 weeks. The initial recommend-
ed dose is 300 mg, which can be doubled every 2–3 days
to reach the maximum dose of 900–2400 mg/day.
Adverse effects include drowsiness, weakness and abnor-
malities of kidney function. These effects are lesser and
usually better tolerated in old patients compared to those
observed with carbamazepine and phenytoin. 
Pregabalin
Pregabalin shares the same activity of gabapentin, with
better pharmacokinetics. Besides its efficacy in pain con-
trol in post-herpetic and diabetic neuropathies, recently
pregabalin has been proven to be effective in an open
pharmaceutical study showing that 74% of patients
improve up to 50% and that efficacy reduction over a
year is minor [61]. This study also highlights that
patients with a concomitant chronic facial pain are less
prone to benefit from treatment. Initially pregabalin can
be administered at 75 mg and can be increased up to 600
mg in two separated daily doses. Drowsiness and dizzi-
ness are the most common side effects and they tend to
recede after a few days of treatment. Higher doses can
cause headache, peripheral oedema and dry mouth. 
Lamotrigine
Lamotrigine is effective both alone and in combination
with carbamazepine or phenytoin [62, 63] especially in
elderly patients and in patients with MS with mild symp-
toms. The drug acts on sodium channels and it stabilises
the plasma membrane, preventing neurotransmitter
release, especially glutamate. Therapeutic dose is
between 100 and 400 mg/day, which needs to be slowly
achieved. Side effects are skin rashes, dizziness, consti-
pation, nausea and drowsiness. 
Topiramate
Topiramate has been proved effective in isolated clinical
trials, in patients with MS and TN [64, 65]. It has a mul-
tiple mechanism of action including: blockage of sodium
channels; and enhancement of GABA activity in the CNS
via interaction with a specific site of action of the GABA
A receptors, which is different from the benzodiazepine
site of action. Topiramate also inhibits glutamergic exci-
tatory activity through blockage of the AMPA/kainate
receptor. Moreover, it inhibits specific carbonic anhy-
drase isoenzymes. The starting dose is 25 mg/day, which
can be increased by 25 mg every week up to a dose of
100–400 mg/day. Side effects include dizziness, double
vision, cognitive impairment, weight loss and high
endocular pressure. 
Baclofen
Baclofen deserves particular attention. It is not an anti-
convulsant agent, rather it can be risky for targeting
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epilepsy when abruptly stopped. Mechanism of action is
at the central level and not on the peripheral nerve.
Baclofen mimics GABA and acts on GABA receptors,
slowing the influx of calcium ions, therefore decreasing
the release of excitatory neurotransmitters. It is slightly
less potent than carbamazepine and can be used as first
choice or in combination with carbamazepine and pheny-
toin (synergism) [66]. 
Starting dose is 5–10 mg/day, which can be slowly
increased until a satisfactory clinical response is
achieved, which is usually 50–75 mg three times a day.
Side effects are usually transient and appear at the begin-
ning of treatment. They include postural hypotension,
muscle weakness and gastroenteric discomfort. About
10% of patients show intolerance to the drug. Patients
with MS also experience extra benefit from the anti-spas-
tic effect of baclofen. 
Other medications
Subcutaneous sumatriptan
Sumatriptan and zolmitriptan showed efficacy in control-
ling allodynic pain following nerve injury in an animal
model for trigeminal neuropathic pain. Both medications
have agonistic action on 5-HT1B, which results in inhibi-
tion of neurons of the trigeminal nucleus localised in the
medulla. Therefore these drugs are thought to act on the
central nervous system [67]. These data were confirmed
in another clinical single-blind study of subcutaneous
sumatriptan vs. placebo. Results proved efficacy of
sumatriptan on pain symptoms in patients with TN after
15 and 30 min compared to placebo. Benefits lasted for
7 h on average and this limits the clinical use of the drug.
Potential side effects from subcutaneous injection of
sumatriptan include increased blood pressure, nausea
and weakness, which are not dangerous [49]. 
Botulinum toxin
BoNT-A has been used for a long time in the treatment
of disorders characterised by pathologically increased
muscle tone. Early observations in dystonia also demon-
strated an analgesic effect of BoNT-A [68], which led to
further investigation on its efficacy for painful condi-
tions including neuropathic pain [50], low back pain
[69] and headaches [70]. Evidence shows that BoNT-A
reduces the local release of nociceptive neuropeptides
such as substance P, glutamate and calcitonin gene-relat-
ed peptide and inhibits peripheral sensitisation, which
would result in decreased central sensitisation [51].
Hence it can be hypothesised that BoNT-A prevents
peripheral sensitisation and subsequently central sensiti-
sation. There are reports of isolated cases of NT
responding to BoNT-A. In another open study, 13
patients showed significant relief from symptoms after
treatment with BoNT-A [71].
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